EMEA guidance on TB in Remicade users

The EMEA has issued recommendations for the use of Centocor's Remicade infliximab, in response to 28 worldwide post-marketing reports of tuberculosis (TB) infection in patients receiving the

Read the full 279 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE